A Potential Rebound for Hims & Hers Amid Regulatory and Legal Crosswinds

After a punishing multi-month decline, shares of telehealth provider Hims & Hers are showing tentative signs of life. This nascent recovery follows a perfect storm of regulatory warnings and legal challenges that erased more than half of the company’s market value since the start of the year. The recent upward movement is fueled by a confluence of factors: robust annual results, a major strategic acquisition, and the prospect of a favorable shift in U.S. drug policy.

The Catalysts for Decline and a Fragile Recovery

To understand the current bounce, one must first consider the severity of the preceding sell-off. The stock’s 50% plunge in 2025 was triggered by a rapid succession of negative developments. Key among them were advisories from the U.S. Food and Drug Administration (FDA) concerning unauthorized copycat drugs, a patent infringement lawsuit filed by pharmaceutical giant Novo Nordisk, and new restrictions on the shipment of compounded GLP-1 agonist medications.

The present share price advance appears less tied to a single catalyst and more to a delayed reassessment by investors, who are now weighing a batch of recent positive updates against the deeply discounted valuation.

Financial Performance and a Billion-Dollar Expansion

The company’s fundamental case received support from its 2025 annual report. Hims & Hers reported a 59% surge in revenue to $2.35 billion, achieving net income of approximately $128 million. However, management’s guidance for Q1 2026 initially disappointed the market, as it projected that regulatory hurdles could cost around $65 million in sales.

In a significant strategic move to reduce reliance on the U.S. market and specific product categories, the firm announced an agreement to acquire Australian digital health company Eucalyptus for up to $1.15 billion. This transaction grants Hims & Hers immediate access to growing customer bases in the United Kingdom, Germany, and Australia. Eucalyptus is currently growing at a triple-digit percentage rate and is nearing profitability.

Should investors sell immediately? Or is it worth buying Hims & Hers?

A Regulatory Lifeline from Washington?

Perhaps the most intriguing development for future growth came from the political arena. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. indicated that numerous peptides previously on an FDA prohibition list could be reinstated for use by licensed compounding pharmacies.

Such a policy reversal would represent a strategic win for Hims & Hers. The company is already developing a peptide-based product line and acquired a dedicated manufacturing facility for it in 2025. Formal FDA action to loosen these restrictions could help diversify its weight-management business and decrease dependence on the controversial drug semaglutid.

Persistent Risks and Legal Overhangs

Despite these operational strides, significant risks cloud the outlook. Trading at a recent price of around €13.71, the equity remains deeply in bear market territory and far below its 52-week high near €58.

Substantial legal uncertainties also persist. Beyond the Novo Nordisk patent dispute, Hims & Hers is subject to ongoing investigations by the Securities and Exchange Commission (SEC) and the Department of Justice related to the marketing of unapproved medications. While CEO Andrew Dudum has emphasized the resilience of the business model even without weight-loss drugs, market skepticism remains high.

The current recovery is essentially a bet that international expansion and new product categories can offset ongoing regulatory headaches in the United States. Until the various legal battles and federal probes are conclusively resolved, volatility is likely to remain the defining characteristic of this stock.